MicroRNA 4483 (miR-4483)

MicroRNA 4483 (miR-4483) is a small, endogenous non-coding RNA molecule, part of the microRNA (miRNA) family, encoded in the human genome and annotated as hsa-miR-4483. MicroRNAs, including miR-4483, function primarily as post-transcriptional regulators of gene expression by binding to complementary sequences in the 3' untranslated regions (UTRs) of target messenger RNAs (mRNAs), leading to either mRNA degradation or translational inhibition[1][2][3][4][6]. The overall effects are modulation of diverse cellular processes such as cell proliferation, differentiation, apoptosis, and developmental pathways, depending on the complement of gene targets in specific cell types[2][3][4][6]. There is currently insufficient evidence to define miR-4483 as a therapeutic target, a biomarker, or a drug-interacting entity, and reporting on specific roles in disease or pharmacology remains limited. MicroRNAs in general are emerging factors in cancer biology, immune regulation, and cell fate determination, but there's no well-established disease association or clinical application for miR-4483 specifically[1][2][5][6]. miR-4483 is named according to standard Human Genome Organization (HUGO) conventions for microRNAs (MIR4483 for the gene, hsa-miR-4483 for the mature product). As for most microRNAs, alternative names follow miRBase and HUGO nomenclature standards. While microRNAs as a class can be involved in diseases such as cancer, cardiovascular disease, and immune dysregulation[5][6], there is currently no published evidence establishing miR-4483 in a major disease category or as a direct therapeutic target. No reports were identified for drugs or interventions targeting miR-4483 specifically in clinical or preclinical therapeutics. If specific structured information about miR-4483 in disease, therapy, or drug development emerges in the future, those entries should be updated accordingly.

Other names

hsa-miR-4483MIR4483hsa-mir-4483